These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 35132950)

  • 1. Accelerating the discovery of the beyond rule of five compounds that have high affinities toward SARS-CoV-2 spike RBD.
    Abu-Saleh AAA; Yadav A; Poirier RA
    J Biomol Struct Dyn; 2023 Apr; 41(6):2518-2527. PubMed ID: 35132950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myxobacterial depsipeptide chondramides interrupt SARS-CoV-2 entry by targeting its broad, cell tropic spike protein.
    Fernandez RA; Quimque MT; Notarte KI; Manzano JA; Pilapil DY; de Leon VN; San Jose JJ; Villalobos O; Muralidharan NH; Gromiha MM; Brogi S; Macabeo APG
    J Biomol Struct Dyn; 2022; 40(22):12209-12220. PubMed ID: 34463219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of mutation on structure, function and dynamics of receptor binding domain of human SARS-CoV-2 with host cell receptor ACE2: a molecular dynamics simulations study.
    Dehury B; Raina V; Misra N; Suar M
    J Biomol Struct Dyn; 2021 Nov; 39(18):7231-7245. PubMed ID: 32762417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vitamin D3 and its hydroxyderivatives as promising drugs against COVID-19: a computational study.
    Song Y; Qayyum S; Greer RA; Slominski RM; Raman C; Slominski AT; Song Y
    J Biomol Struct Dyn; 2022; 40(22):11594-11610. PubMed ID: 34415218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug repurposing against SARS-CoV-2 receptor binding domain using ensemble-based virtual screening and molecular dynamics simulations.
    Kumar V; Liu H; Wu C
    Comput Biol Med; 2021 Aug; 135():104634. PubMed ID: 34256255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular dynamics analysis predicts ritonavir and naloxegol strongly block the SARS-CoV-2 spike protein-hACE2 binding.
    Bagheri M; Niavarani A
    J Biomol Struct Dyn; 2022 Mar; 40(4):1597-1606. PubMed ID: 33030105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural stability predictions and molecular dynamics simulations of RBD and HR1 mutations associated with SARS-CoV-2 spike glycoprotein.
    Ahamad S; Hema K; Gupta D
    J Biomol Struct Dyn; 2022 Sep; 40(15):6697-6709. PubMed ID: 33618621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In silico binding profile characterization of SARS-CoV-2 spike protein and its mutants bound to human ACE2 receptor.
    Zhang Y; He X; Zhai J; Ji B; Man VH; Wang J
    Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34013346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-throughput virtual screening of drug databanks for potential inhibitors of SARS-CoV-2 spike glycoprotein.
    Awad IE; Abu-Saleh AAA; Sharma S; Yadav A; Poirier RA
    J Biomol Struct Dyn; 2022 Mar; 40(5):2099-2112. PubMed ID: 33103586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ACE2-derived peptides interact with the RBD domain of SARS-CoV-2 spike glycoprotein, disrupting the interaction with the human ACE2 receptor.
    Souza PFN; Amaral JL; Bezerra LP; Lopes FES; Freire VN; Oliveira JTA; Freitas CDT
    J Biomol Struct Dyn; 2022 Aug; 40(12):5493-5506. PubMed ID: 33427102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced Binding of SARS-CoV-2 Spike Protein to Receptor by Distal Polybasic Cleavage Sites.
    Qiao B; Olvera de la Cruz M
    ACS Nano; 2020 Aug; 14(8):10616-10623. PubMed ID: 32806067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Novel Therapeutic Peptide Blocks SARS-CoV-2 Spike Protein Binding with Host Cell ACE2 Receptor.
    Rajpoot S; Ohishi T; Kumar A; Pan Q; Banerjee S; Zhang KYJ; Baig MS
    Drugs R D; 2021 Sep; 21(3):273-283. PubMed ID: 34324175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In silico exploration of small-molecule α-helix mimetics as inhibitors of SARS-COV-2 attachment to ACE2.
    Hakmi M; Bouricha ELM; Akachar J; Lmimouni B; El Harti J; Belyamani L; Ibrahimi A
    J Biomol Struct Dyn; 2022 Mar; 40(4):1546-1557. PubMed ID: 33023417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Truncated human angiotensin converting enzyme 2; a potential inhibitor of SARS-CoV-2 spike glycoprotein and potent COVID-19 therapeutic agent.
    Basit A; Ali T; Rehman SU
    J Biomol Struct Dyn; 2021 Jul; 39(10):3605-3614. PubMed ID: 32396773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathway enrichment analysis of virus-host interactome and prioritization of novel compounds targeting the spike glycoprotein receptor binding domain-human angiotensin-converting enzyme 2 interface to combat SARS-CoV-2.
    Gollapalli P; B S S; Rimac H; Patil P; Nalilu SK; Kandagalla S; Shetty P
    J Biomol Struct Dyn; 2022 Apr; 40(6):2701-2714. PubMed ID: 33146070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Withanone from
    Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A
    Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The molecular dynamics of possible inhibitors for SARS-CoV-2.
    Irani AH; Steyn-Ross DA; Steyn-Ross ML; Voss L; Sleigh J
    J Biomol Struct Dyn; 2022; 40(20):10023-10032. PubMed ID: 34229582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In a search for potential drug candidates for combating COVID-19: computational study revealed salvianolic acid B as a potential therapeutic targeting 3CLpro and spike proteins.
    Elmaaty AA; Darwish KM; Khattab M; Elhady SS; Salah M; Hamed MIA; Al-Karmalawy AA; Saleh MM
    J Biomol Struct Dyn; 2022; 40(19):8866-8893. PubMed ID: 33928870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-based virtual screening and molecular docking of drugs against the SARS-CoV-2 spike protein-ACE2 receptor complex.
    Ahmad I; Ali M; Ali R; Nawaz N; G Patching S
    Pak J Pharm Sci; 2022 Nov; 35(6):1531-1538. PubMed ID: 36789812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of SARS-CoV-2 pathogenesis by potent peptides designed by the mutation of ACE2 binding region.
    Pourmand S; Zareei S; Shahlaei M; Moradi S
    Comput Biol Med; 2022 Jul; 146():105625. PubMed ID: 35688710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.